HuGE Literature Finder
Records
1
-
22
| Lab tests for MPN. International review of cell and molecular biology 2022 2 366 187-220. Moncada Alice, Pancrazzi Alessand |
| TET2 Mutation May Be More Valuable in Predicting Thrombosis in ET Patients Compared to PV Patients: A Preliminary Report. Journal of clinical medicine 2022 11 11 (22): . Wang Ziqing, Liu Weiyi, Wang Dehao, Yang Erpeng, Li Yujin, Li Yumeng, Sun Yan, Wang Mingjing, Lv Yan, Hu Xiaom |
| TET2, DNMT3A, IDH1, and JAK2 Mutation in Myeloproliferative Neoplasms in southern Iran. International journal of organ transplantation medicine 2022 5 12 (3): 12-20. Abedi E, Ramzi M, Karimi M, Yaghobi R, Mohammadi H, Bayat E, Moghadam M, Farokhian F, Dehghani M, Golafshan H A, Haghpanah |
| Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression. European journal of haematology 2021 1 106 (4): 520-528. Bartels Stephan, Vogtmann Julia, Schipper Elisa, Büsche Guntram, Schlue Jerome, Lehmann Ulrich, Kreipe Ha |
| JAK2 and TET2 Mutation in Polycythemia Vera. Cureus 2021 10 13 (9): e17854. Padda Jaskamal, Khalid Khizer, Yadav Jayant, Almanie Abdulelah H, Mehta Krutagni Adwait, Al Hennawi Hussam, Boddeti Nymisha L, Campos Victor Yosef Melt, Jean-Charles Gutterid |
| Mutational profiling in myelofibrosis: implications for management. International journal of hematology 2019 10 111 (2): 192-199. Bose Prithviraj, Verstovsek Srd |
| Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis. American journal of clinical pathology 2017 May 147 (5): 444-452. Song Jinming, Hussaini Mohammad, Zhang Hailing, Shao Haipeng, Qin Dahui, Zhang Xiaohui, Ma Zhenjun, Hussnain Naqvi Syeda Mahrukh, Zhang Ling, Moscinski Lynn |
| Monocytosis in polycythemia vera: Clinical and molecular correlates. American journal of hematology 2017 Mar . Barraco Daniela, Cerquozzi Sonia, Gangat Naseema, Patnaik Mrinal M, Lasho Terra, Finke Christy, Hanson Curtis A, Ketterling Rhett P, Pardanani Animesh, Tefferi Ayal |
| TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms. Turkish journal of haematology : official journal of Turkish Society of Haematology 2017 Feb . Soyer Nur, Tezcanl? Kaymaz Burçin, Cömert Özkan Melda, Aktan Ça?da?, Küçükaslan Ali ?ahin, ?ahin Fahri, Kosova Buket, Saydam Gür |
| Bone marrow findings in blast phase of polycythemia vera. Annals of hematology 2017 12 97 (3): 425-434. Hidalgo López Juliana E, Carballo-Zarate Adrian, Verstovsek Srdan, Wang Sa A, Hu Shimin, Li Shaoying, Xu Jie, Zuo Wenli, Tang Zhenya, Yin C Cameron, Medeiros L Jeffrey, Bueso-Ramos Carlos E, Tang Guil |
| Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood cancer journal 2017 12 7 (12): 662. Cerquozzi S, Barraco D, Lasho T, Finke C, Hanson C A, Ketterling R P, Pardanani A, Gangat N, Tefferi |
| Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. Blood 2016 Jun . Hinds David A, Barnholt Kimberly E, Mesa Ruben A, Kiefer Amy K, Do Chuong B, Eriksson Nicholas, Mountain Joanna L, Francke Uta, Tung Joyce Y, Nguyen Huong Marie, Zhang Haiyu, Gojenola Linda, Zehnder James L, Gotlib Jas |
| Analysis of the Ten-Eleven Translocation 2 (TET2) gene mutation in myeloproliferative neoplasms. Annals of clinical and laboratory science 2014 44 (2): 173-9. Ha Jung-Sook, Jeon Dong-Seok, Kim Jae-Ryong, Ryoo Nam-Hee, Suh Jang-S |
| Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a-2a. Blood 2013 Aug 122 (6): 893-901. Quintás-Cardama Alfonso, Abdel-Wahab Omar, Manshouri Taghi, Kilpivaara Outi, Cortes Jorge, Roupie Anne-Laure, Zhang Su-Jiang, Harris David, Estrov Zeev, Kantarjian Hagop, Levine Ross L, Verstovsek Srd |
| TET2 mutations in Ph-negative myeloproliferative neoplasms: identification of three novel mutations and relationship with clinical and laboratory findings. BioMed research international 2013 2013 929840. Patriarca Andrea, Colaizzo Donatella, Tiscia Gianluca, Spadano Raffaele, Di Zacomo Silvia, Spadano Antonio, Villanova Ida, Margaglione Maurizio, Grandone Elvira, Dragani Alfre |
| Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases. Haematologica 2012 Dec 97 (12): 1890-4. Schnittger Susanne, Bacher Ulrike, Alpermann Tamara, Reiter Andreas, Ulke Madlen, Dicker Frank, Eder Christiane, Kohlmann Alexander, Grossmann Vera, Kowarsch Andreas, Kern Wolfgang, Haferlach Claudia, Haferlach Torst |
| Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow. Haematologica 2012 Oct 97 (10): 1582-5. Schnittger Susanne, Bacher Ulrike, Eder Christiane, Dicker Frank, Alpermann Tamara, Grossmann Vera, Kohlmann Alexander, Kern Wolfgang, Haferlach Claudia, Haferlach Torst |
| Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes, chromosomes & cancer 2012 Aug 51 (8): 743-55. Brecqueville Mandy, Rey Jérôme, Bertucci François, Coppin Emilie, Finetti Pascal, Carbuccia Nadine, Cervera Nathalie, Gelsi-Boyer Véronique, Arnoulet Christine, Gisserot Olivier, Verrot Denis, Slama Borhane, Vey Norbert, Mozziconacci Marie-Joelle, Birnbaum Daniel, Murati An |
| TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms. Annals of hematology 2012 Apr 91 (4): 533-41. Martínez-Avilés Luz, Besses Carlos, Álvarez-Larrán Alberto, Torres Erica, Serrano Sergi, Bellosillo Beatr |
| IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010 Jul 24 (7): 1302-9. Tefferi A, Lasho T L, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D, Pieri L, Finke C M, Kilpivaara O, Wadleigh M, Mai M, McClure R F, Gilliland D G, Levine R L, Pardanani A, Vannucchi A |
| Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms. Cancer management and research 2010 12 2 219-23. Tripodi Joseph, Hoffman Ronald, Najfeld Vesna, Weinberg Ro |
| TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009 May 23 (5): 905-11. Tefferi A, Pardanani A, Lim K-H, Abdel-Wahab O, Lasho T L, Patel J, Gangat N, Finke C M, Schwager S, Mullally A, Li C-Y, Hanson C A, Mesa R, Bernard O, Delhommeau F, Vainchenker W, Gilliland D G, Levine R |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 21, 2023
- Content source: